Liraglutide
Also known as: Victoza, Saxenda
Daily GLP-1 receptor agonist: first-gen, shorter acting than semaglutide.
- Typical dose
- 600 mcg – 3 mg
- Frequency
- once daily
- Route
- Subcutaneous
- Half-life
- 13 hours
- Routes
- Subcutaneous
- Status
- FDA-approved (Victoza for T2D, Saxenda for weight management)
Benefits
- Weight loss
- Blood sugar control
- Cardiovascular benefit
Dosing
A common research range for Liraglutide is 600 mcg to 3 mg once daily. Titrate 0.6mg/wk increments to 3.0mg. These figures are reference points from published literature, not a prescription — your protocol should be set with a licensed provider.
Half-life
Liraglutide has an approximate half-life of 13 hours. Vial plots the real concentration curve from your logged doses so you can see peak windows and when levels taper.
Storage
2-8°C; room temp up to 30 days.
Reported side effects
- Nausea
- Diarrhea
- Constipation
- Headache
Contraindications
- Personal/family history of MTC
- MEN 2 syndrome
Track Liraglutide with Vial
Vial logs every Liraglutide dose, plots its half-life curve, calculates reconstitution math, and keeps your whole protocol on schedule — on-device and private. Download Vial on the App Store →
This page is for educational and harm-reduction purposes only. Liraglutide is not FDA-approved for most uses described here. Always consult a licensed physician before starting any peptide protocol. Vial does not sell peptides, recommend vendors, or provide medical advice.